Dave Sukruti, Choudhury Arpan, Alurkar Shirish S, Shah Akash M
Department of Medical Oncology, Apollo Hospitals International Limited: Apollo Hospitals Ahmedabad, Ahmedabad, Gujarat India.
Department of Surgical Oncology, Apollo Hospitals International Limited: Apollo Hospitals Ahmedabad, Ahmedabad, Gujarat India.
Indian J Surg Oncol. 2024 Mar;15(1):44-52. doi: 10.1007/s13193-023-01822-9. Epub 2023 Sep 29.
Neoadjuvant chemotherapy (NACT) is routinely offered to operable locally advanced breast cancer (LABC) patients desirous of breast conservation surgery and inoperable LABC patients. Pathological complete response (pCR) following chemotherapy is recognized as a surrogate for survival outcomes in high grade tumour subtypes. Many biological and tumor characters have been shown to predict pCR. The current study was performed with the aim of investigating the ability of Ki-67 in predicting pCR with NACT in breast cancer patients. A total of 105 patients with locally advanced breast cancer who completed NACT followed by surgery were included in this study from January 2020 till December 2022. Patients with advanced metastatic breast carcinoma, who did not give consent for NACT, who did not complete NACT and who did not undergo surgery were excluded. All patients were assessed for Ki-67 score on core-needle biopsy samples and response rate was assessed clinically and by histopathological examination of resected specimen. Quantitative variables were compared using unpaired t-test or Mann-Whitney 'U' test and for categorical variables Chi-square or Fisher's exact test were used. Receiver operating characteristic (ROC) curve analysis was performed to assess the predictive potential of Ki-67 expression levels in predicting pCR. To identify the predictive factors associated with pCR, univariate analysis was performed. The value < 0.05 was considered as statistically significant. Mean age was 51.57 ± 10.8 years. 51 patients achieved clinical complete response (cCR) and 33 achieved pCR after NACT. Mean Ki-67 index in overall study population, in pCR group and no pCR group was 46.44 ± 22.92%, 51.60 ± 22.3% and 44.06 ± 22.7%, respectively. On univariate analysis, ER negativity, PR negativity and Her 2neu positivity were found predictive of pCR. On subgroup analysis, TNBC and Her 2neu positive sub groups were associated with higher cCR and pCR rate. We found no significant association between Ki-67 and pCR. This result may be confounded by the fact that a significant duration of the study was in the COVID-19 pandemic. Validation of this data is required in a large prospective study.
新辅助化疗(NACT)通常适用于希望进行保乳手术的可手术局部晚期乳腺癌(LABC)患者以及不可手术的LABC患者。化疗后的病理完全缓解(pCR)被认为是高级别肿瘤亚型生存结果的替代指标。许多生物学和肿瘤特征已被证明可预测pCR。本研究旨在调查Ki-67在预测乳腺癌患者NACT后pCR方面的能力。本研究纳入了2020年1月至2022年12月期间共105例完成NACT后接受手术的局部晚期乳腺癌患者。排除了晚期转移性乳腺癌患者、未同意接受NACT的患者、未完成NACT的患者以及未接受手术的患者。所有患者均在粗针活检样本上评估Ki-67评分,并通过临床评估和对切除标本的组织病理学检查评估缓解率。定量变量采用非配对t检验或Mann-Whitney “U”检验进行比较,分类变量采用卡方检验或Fisher精确检验。进行受试者操作特征(ROC)曲线分析以评估Ki-67表达水平在预测pCR方面的预测潜力。为了确定与pCR相关的预测因素,进行了单因素分析。P值<0.05被认为具有统计学意义。平均年龄为51.57±10.8岁。51例患者在NACT后达到临床完全缓解(cCR),33例达到pCR。总体研究人群、pCR组和非pCR组的平均Ki-67指数分别为46.44±22.92%、51.60±22.3%和44.06±22.7%。单因素分析发现,雌激素受体阴性、孕激素受体阴性和人表皮生长因子受体2(Her 2neu)阳性可预测pCR。亚组分析显示,三阴性乳腺癌(TNBC)和Her 2neu阳性亚组的cCR和pCR率较高。我们发现Ki-67与pCR之间无显著关联。这一结果可能受到以下事实的混淆,即本研究的相当长一段时间处于新冠疫情期间。需要在一项大型前瞻性研究中对这些数据进行验证。